EQ VS PHGE Stock Comparison

Performance

EQ
10/100

EQ returned -70.89% in the last 12 months. Based on SPY's performance of -16.09%, its performance is below average giving it a score of 10 of 100.

PHGE
100/100

PHGE returned 40.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

EQ
100/100

2 analysts offer 12-month price targets for EQ. Together, they have an average target of 0, the most optimistic target put EQ at 0 within 12-months and the most pessimistic has EQ at 0.

PHGE

"Analyst Price Targets" not found for PHGE

Sentiment

EQ
72/100

EQ had a bullish sentiment score of 71.71% across Twitter and StockTwits over the last 12 months. It had an average of 4.25 posts, 3.92 comments, and 7.17 likes per day.

PHGE

"Sentiment" not found for PHGE

Technicals

EQ
10/100

EQ receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

PHGE
82/100

PHGE receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.

Earnings

EQ
10/100

EQ has missed earnings 8 times in the last 20 quarters.

PHGE
100/100

PHGE has missed earnings 1 times in the last 20 quarters.

Profit

EQ
10/100

Out of the last 20 quarters, EQ has had 1 profitable quarters and has increased their profits year over year on 1 of them.

PHGE
10/100

Out of the last 20 quarters, PHGE has had 3 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

EQ
34/100

EQ has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

PHGE
44/100

PHGE has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Equillium, Inc. Common Stock Summary

Nasdaq / EQ

Healthcare

Biotechnology

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

BiomX Inc. Summary

Healthcare

Biotechnology

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Power up your portfolio